Oncologists

Theralink Technologies will provide the treating physician an entirely new and powerful source of precision medicine through its Theralink assay. Starting with Breast Cancer, and then planned for most solid tumors, Theralink will assist the treating physician in a data-driven process for treatment decision support and enable new predictive protein biomarker-based selection.

Theralink is the leading developer of phosphoproteomic technologies, that for the first time ever, can measure the activation state of key drug targets and signaling pathways within a microscopic quantity of tumor sample. Theralink’s applications are across multiple cancer types, including but not limited to, breast, non-small cell lung, colorectal and pancreatic. Measuring the direct activation state of dozens of drug targets at once provides key information about the tumor missed entirely by current genomic and transcriptomic assays.

Theralink was developed to empower physicians with new potential sources of actionable information to help them make time-sensitive treatment decisions for their patients.

Theralink was designed to provide new protein and phosphoprotein biomarkers through the direct and quantitative measurement of the expression levels of a protein drug target and pathway surrounding it – making Theralink instrumental in the development of molecular targeted therapies.

The information gathered through measurement of the drug target activation landscape has the potential to both increase the frequency of actionable findings as well as help physicians make molecular rationalized treatment decisions that could improve treatment outcomes and reduce side effects by foregoing ineffective therapies.